Movers & Shakers

We’ve seen some improvement in the market in recent days, with the major indexes rallying nicely. Most of the action has been in the beaten-down sectors of the market (commodities, oil, etc.), which isn’t ideal; the big “problem” with the market this year has been the various crosscurrents and divergences underneath the market’s hood.

We don’t see the recent strength from the beaten-down groups as a bad thing. Far from it! At the end of the day, if the market is going to enter an uptrend, we’re going to have to see these groups at least stabilize, if not rally back somewhat. So, simply, up is good.

Now, with all that said, the rally of the past few days hasn’t changed our overall view—the intermediate-term trend is down (or, if you prefer, sideways-to-down), and few stocks are making much progress on the upside. The Nasdaq remains the strongest index, which is usually a positive, but we need to see more sustained strength to get a buy signal.

Thus, we advise continued caution—some small buys here or there are fine, as is holding your strong performers. But you should have a good-sized cash position and keep your laggards on tight leashes.  

Should we see most major indexes rise back above their 50-day lines and see some stocks break out powerfully to new highs, we’ll become more aggressive. And if we see a move to new highs in the indexes, we’ll shout from the rooftops! But for now, there’s still not many stocks running away on the upside, so hold some top performers and practice patience until the bulls take control.

This is an excerpt from Cabot Growth Investor, where we’ve been picking the best growth stocks since 1970. Cabot’s flagship advisory combines expert stock selection and award-winning market timing. It’s the most complete and most helpful, growth-oriented investing advisory available anywhere.

Michael Cintolo is Cabot's Vice President of Investments and Chief Analyst of Cabot Growth Investor and Cabot Top Ten Trader. To read customer reviews of Cabot Top Ten Trader, click here. To read reviews of Cabot Growth Investor, click here.

Michael Cintolo can be found on Google Plus.

Headline News

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.


Biogen is the market-share leader in treating multiple sclerosis.


One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >